Rachel Grisham MD

Gynecologic Cancer, Hematologic Oncology

Associate Attending, Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College; Section Head of Ovarian Cancer; Director Gynecologic Medical Oncology MSKCC Westchester

Request Appointment

500 Westchester AvenueWest Harrison, NY 10604
Book by Phone+1(706) 553-7816

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2006 - 2009
Duke University School of MedicineClass of 2006

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2027
NY State Medical License 2009 - 2026
CT State Medical License 2023 - 2025
NC State Medical License 2020 - 2022
MA State Medical License 2008 - 2009
American Board of Internal Medicine Medical Oncology

Clinical Trials

Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies Start of enrollment: 2013 Nov 05
Completed
Phase 2
A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone Start of enrollment: 2019 May 02
COMPLETED
PHASE2
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Start of enrollment: 2020 May 07
ACTIVE_NOT_RECRUITING
PHASE1
Nirogacestat in Ovarian Granulosa Cell Tumors Start of enrollment: 2022 Aug 30
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer Start of enrollment: 2023 Mar 15
RECRUITING
PHASE2
Roles: Principal Investigator, Contact
A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy Start of enrollment: 2024 Jan 26
RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

4 citations
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.
Angela K Green, Qin Zhou, Alexia Iasonos, William A Zammarrelli 3rd, Britta Weigelt
Clinical Cancer Research. 2025-06-03
Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeutics.
Kari L Ring, Anne M Mills, Brooke E Howitt, Rachel N Grisham, Elizabeth D Euscher
Gynecologic Oncology. 2025-06-01
Repurposing Food and Drug Administration-approved cancer therapies: exploring endocrine and targeted pathways in low-grade serous ovarian cancer treatment.
Vivek Podder, Rachel N Grisham, Robert L Coleman, Lauren Patterson Cobb, Bradley J Monk
International Journal of Gynecological Cancer. 2025-05-15

Lectures

Low Grade Ovarian Carcinoma: Fitting the Square Peg into the Round Hole
ASCO Annual Meeting 2019 - Chicago, IL - 5/3/2019
Gynecologic Cancer
ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019

Press Mentions

FDA Approves First-Ever Drug Combo for Low-Grade Serous Ovarian CancerMay 9th, 2025
Accelerated FDA Approval Makes Verastem Drug the First Therapy for Rare Type of Ovarian CancerMay 8th, 2025
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-Mutated Recurrent Low-Grade Serous Ovarian CancerMay 8th, 2025
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
Empire BCBS HMO
Empire BCBS PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment